Łusiak-Szelachowska Marzanna, Zaczek Maciej, Weber-Dąbrowska Beata, Międzybrodzki Ryszard, Kłak Marlena, Fortuna Wojciech, Letkiewicz Sławomir, Rogóż Paweł, Szufnarowski Krzysztof, Jończyk-Matysiak Ewa, Owczarek Barbara, Górski Andrzej
Viral Immunol. 2014 Aug;27(6):295-304. doi: 10.1089/vim.2013.0128. Epub 2014 Jun 3.
The aim of our investigation was to verify whether phage therapy (PT) can induce antiphage antibodies. The antiphage activity was determined in sera from 122 patients from the Phage Therapy Unit in Wrocław with bacterial infections before and during PT, and in sera from 30 healthy volunteers using a neutralization test. Furthermore, levels of antiphage antibodies were investigated in sera of 19 patients receiving staphylococcal phages and sera of 20 healthy volunteers using enzyme-linked immunosorbent assay. The phages were administered orally, locally, orally/locally, intrarectally, or orally/intrarectally. The rate of phage inactivation (K) estimated the level of phages' neutralization by human sera. Low K rates were found in sera of healthy volunteers (K ≤ 1.73). Low K rates were detected before PT (K ≤ 1.64). High antiphage activity of sera K > 18 was observed in 12.3% of examined patients (n = 15) treated with phages locally (n = 13) or locally/orally (n = 2) from 15 to 60 days of PT. High K rates were found in patients treated with some Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecalis phages. Low K rates were observed during PT in sera of patients using phages orally (K ≤ 1.04). Increased inactivation of phages by sera of patients receiving PT decreased after therapy. These results suggest that the antiphage activity in patients' sera depends on the route of phage administration and phage type. The induction of antiphage activity of sera during or after PT does not exclude a favorable result of PT.
我们研究的目的是验证噬菌体疗法(PT)是否能诱导抗噬菌体抗体。采用中和试验测定了弗罗茨瓦夫噬菌体治疗科122例细菌感染患者在接受PT前和治疗期间血清中的抗噬菌体活性,以及30名健康志愿者血清中的抗噬菌体活性。此外,采用酶联免疫吸附测定法研究了19例接受葡萄球菌噬菌体治疗的患者血清和20名健康志愿者血清中的抗噬菌体抗体水平。噬菌体通过口服、局部、口服/局部、直肠内或口服/直肠内给药。噬菌体失活率(K)估计了人血清对噬菌体的中和水平。在健康志愿者血清中发现低K率(K≤1.73)。在PT前检测到低K率(K≤1.64)。在接受噬菌体局部治疗(n = 13)或局部/口服治疗(n = 2)的15至60天的12.3%的受检患者(n = 15)中观察到血清的高抗噬菌体活性(K>18)。在使用某些金黄色葡萄球菌、铜绿假单胞菌和粪肠球菌噬菌体治疗的患者中发现高K率。在口服噬菌体的患者血清中,PT期间观察到低K率(K≤1.04)。接受PT的患者血清对噬菌体的失活作用在治疗后降低。这些结果表明,患者血清中的抗噬菌体活性取决于噬菌体给药途径和噬菌体类型。PT期间或之后血清抗噬菌体活性的诱导并不排除PT取得良好效果的可能性。